EBMT China’s Voice | Professors Ke Xiaoyan and Hu Kai’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients with Combined Autologous Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year's conference, two studies conducted by Professor Ke Xiaoyan from Peking University Third Hospital/Beijing Chaoyang Hospital and Professor Hu Kai from Beijing Chaoyang Hospital were presented, highlighting how combined autologous hematopoietic stem cell transplantation and CAR-T cell therapy can improve survival rates for lymphoma and multiple myeloma patients.